Posdinemab
Based on 1 Customer Validation
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: ≥99.0%
- CAS. Nr.: 2517973-04-3
- Molecular Weight:145.331 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG1 kappa
Human
MAPT
Artificial cerebrospinal fluid and mouse brain homogenate experiments[2]:
Posdinemab (100 nM; overnight immunoprecipitation incubation + 20 h enzymatic hydrolysis) specifically binds to phosphorylated tau (p217+tau). The target peptides are enriched by immunoprecipitation, and the dual-phosphorylated tau peptide SRTPSLPTPPTREPK?2p containing the pT217 site can be detected, confirming the antibody's high affinity and selective capture ability for phosphorylated tau[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
2. Posdinemab detects the dual-phosphorylated tau peptide SRTPSLPTPPTREPK?2p (containing the pT217 site) in CSF, and decreases the total p217+tau level after treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Posdinemab on AHC2 biosensor, can bind Fetal-tau/0N3R Protein, Human (His, HY-P73618A) with an affinity constant of 4.928E-07 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 2517973-04-3
-
Appearance Liquid
-
Molecular Weight 145.331 kDa
-
Color Colorless to light yellow
-
SMILES
[Posdinemab]
-
Synonyms
JNJ-63733657
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Galpern WR, et al. Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease. J Prev Alzheimers Dis. 2024;11(6):1592-1603. [Content Brief]
[2]. Bijttebier S, et al. Development of immunoprecipitation - two-dimensional liquid chromatography-mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients. J Chromatogr A. 2021 Aug 16;1651:462299. [Content Brief]
[3]. Panza F, et al. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opin Investig Drugs. 2023 Jul-Dec;32(7):625-634. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Posdinemab Related Classifications
HY-P9995 Related Classifications
Powered by Bioz